Stock analysis for Onxeo SA (ONXEO) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Regulatory News: Do not distribute or disseminate, directly or indirectly, in the United States of America, Canada, Australia or

The company focuses on developing disruptive compounds from preclinical research. It produces and develops orphan oncology products under the brand names Livatag, Validive, Beleodaq, platON, and Köp aktien Onxeo SA (ONXEO). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid A rights issue or rights offer is a dividend of subscription rights to buy additional securities in a company made to the company's existing security holders. When the rights are for equity securities, such as shares, in a public company, it is a non-dilutive(can be dilutive) pro rata way to raise capital.Rights issues are typically sold via a prospectus or prospectus supplement. Onxeo SA is a is a clinical-stage biotechnology company. It engages in the development of drugs for the treatment of orphan diseases.

(3) Capital increase up to 100% The fund raising proposed by Onxeo is a capital increase through the issuance of New Shares with preferential subscription rights (PSR). Prior to the proposed transaction, Onxeo's share capital Onxeo : Launches a Rights Issue to Accelerate Its R&D Programs (1) Taking into account the 4,335,740 options and warrants giving access to the share capital granted and outstanding as (2) Capital increase up to 75.5% of the initial number of new shares to be issued. (3) Capital increase up to ONXEO : Launches a Rights Issue to Accelerate Its R&D Programs: BU. 02/05: ONXEO S A Jones Day represented Onxeo SA, an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, in connection with its €40.7 million (US$50.6 million) issuance of Ordinary Shares. 2014-11-18 · Rights Issue Open to the Public in France and in Denmark Transaction Executed on the Back of Subscription Commitments from the Company's Principal Shareholder, Financiere De La Montagne, and Two 2014-11-18 · Onxeo SA makes a rights issue of up to u p to 7,872,661 new shares.

All persons acting on behalf of the Company (i.e. executives and/or directors) have also signed lock-up agreements with regard to the Company's shares that they hold, for the same period. Onxeo S.A. has been searching for a partner to help develop its drug for a side effect of cancer treatment.

MCT's collaboration with Onxeo on HCC Phase III study in Middle East. Onxeo has engaged MCT (Regional CRO . MCT Insights - Perspectives on issues that are reshaping Clinical Research in Middle East and Africa All Rights Reserv

(3) Capital increase up to 2021-03-11 Rights issue rationale ONXEO targets to become a global leader in oncology, with a focus on orphan or rare cancers, leveraging its three key programs already at an advanced development stage, Beleodaq® (an approved histone deacetylase inhibitor (HDAC) commercialized in the US by partner Spectrum Pharmaceuticals for . 2021-03-17 Onxeo completes €40.7 million rights issue. December 2014.

17 Feb 2016 The North American distribution rights to Sitavig were acquired by Cipher in April 2015 with the acquisition of Innocutis Holdings LLC, which originally licensed the product from Onxeo S.A., ADD TOPIC TO EMAIL ALERTS.

Rights issue main terms This capital increase with shareholder preferential subscription rights will result in the issuance of Onxeo Launches a Rights Issue to Accelerate Its R&D Programs Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage 16 timmar sedan · Zeit Aktuelle Nachrichten; 13:51: Onxeo S.A.: Onxeo Announces the Success of Its Rights Issue With €9.7 Million Raised: This transaction will accelerate the development of the Company and its 4 timmar sedan · Onxeo Announces the Success of Its Rights Issue With €9.7 Million Raised Bioalliance PharmaAct Nom Cat-P Aktie [Valor: 1884147 / ISIN: FR0010095596] Kaufen Verkaufen 16 timmar sedan · Onxeo Announces the Success of Its Rights Issue With €9.7 Million Raised Regulatory News: Do not distribute or disseminate, directly or indirectly, in the United States of America, Canada 1 month Onxeo Launches a Rights Issue to Accelerate Its R&D Programs Business Insider